Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by FredTheVoiceon Apr 10, 2021 5:28pm
130 Views
Post# 32973278

RE:RE:RE:How should the stock react Monday?

RE:RE:RE:How should the stock react Monday? Fun to see that the company is doing a fine job.

And Pipeline, moving along nicely, oncology that said. Was faster than expected, fast track was a nice gift.

But, Wino, and others, on that spring target of 5$ U.S., we will get to it and beat it if we get positive news on two front:

1. We need news that NASH is going forward with phase III. More long it takes, ...just not good for market reaction;
2. Next week earnings: we must see Levesque's effect showing good movement on the sales front.

Because, Oncology wont move the needle that much before next fall......

NASH and sales are the TH Stock shaker for spring and summer.

Enjoy your weekend, and dream of that 200$ a share......

FTV.
<< Previous
Bullboard Posts
Next >>